Yayoi Tada

Itabashi, 1738605, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 265 publications

Early Temporal Dissociation Between C-Reactive Protein and Neutrophil Counts After Spesolimab Treatment in Generalized Pustular Psoriasis.

Early Temporal Dissociation Between C-Reactive Protein and Neutrophil Counts After Spesolimab Treatment in Generalized Pustular Psoriasis.

Journal: Acta dermato-venereologica

Published: June 19, 2026

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan.

Treatment Patterns and Pathways of Systemic Drug Therapy in Patients With Plaque, Erythrodermic, and Generalized Pustular Psoriasis: A Retrospective Cohort Study in Japan.

Journal: The Journal of dermatology

Published: May 15, 2026

Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Characteristics of Real-World Patients with Psoriasis Receiving Guselkumab or Interleukin-17 Inhibitors: Data from the Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Journal: Journal of psoriasis and psoriatic arthritis

Published: May 11, 2026

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

Safety and Efficacy of Deucravacitinib in Japanese Patients With Moderate to Severe Plaque Psoriasis: 5-Year Analysis of the Phase 3 POETYK PSO-1, PSO-4, and Long-Term Extension Trials.

Journal: The Journal of dermatology

Published: April 28, 2026

Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study.

Treatment Persistence of Interleukin-17 Inhibitors and Factors Associated with Persistence in Patients with Psoriasis Vulgaris in Japan: Retrospective Database Study.

Journal: Dermatology and therapy

Published: March 09, 2026

Internalizing sex differences in allergic disease: A sex-dependent airway epithelial immune network.

Internalizing sex differences in allergic disease: A sex-dependent airway epithelial immune network.

Journal: The Journal of allergy and clinical immunology

Published: February 17, 2026

Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis.

Real-world effectiveness and safety of lebrikizumab maintenance dosing every 4 weeks starting at week 4 after 2 loading doses in Japanese patients with atopic dermatitis.

Journal: JAAD international

Published: January 21, 2026

Real-World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP).

Real-World Safety Profile of Spesolimab in Generalized Pustular Psoriasis: Insights From Japan as Part of a Multinational Expanded Access Program (EAP).

Journal: The Journal of dermatology

Published: October 08, 2025

A 308-nm Excimer Lamp Ameliorates MC903-Induced Atopic Dermatitis With Reductions of Intraepidermal Nerve Fiber Density and Expression of Thymic Stromal Lymphopoietin.

A 308-nm Excimer Lamp Ameliorates MC903-Induced Atopic Dermatitis With Reductions of Intraepidermal Nerve Fiber Density and Expression of Thymic Stromal Lymphopoietin.

Journal: The Journal of dermatology

Published: October 01, 2025

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.

Summary of Research: Apremilast in Japanese Patients with Palmoplantar Pustulosis: A Randomized, Phase 3 Trial.

Journal: Dermatology and therapy

Published: October 01, 2025

Real-world safety profile of spesolimab in generalised pustular psoriasis: expanded access programmes in Japan, China and Argentina.

Real-world safety profile of spesolimab in generalised pustular psoriasis: expanded access programmes in Japan, China and Argentina.

Journal: The British journal of dermatology

Published: September 30, 2025

Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study.

Duration of current alopecia areata episode predicts the effectiveness of baricitinib in Japanese patients with alopecia areata: a single-center retrospective study.

Journal: The Journal of dermatological treatment

Published: September 08, 2025

Showing 1-12 of 265

Last Updated: 09/26/2026